CNS Pharmaceuticals is developing novel treatments for primary and metastatic cancers of the brain and central nervous system. Its lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. CNS holds a worldwide exclusive license to the Berubicin chemical compound and has acquired all data and know-how from Reata Pharmaceuticals, Inc. related to a completed Phase 1 trial with Berubicin in GBM which Reata conducted in 2006. In this trial, 44% of patients experienced a statistically significant improvement in progression-free survival. This 44% disease control rate was based on 11 patients (out of 25 evaluable patients) with stable disease, plus responders. One patient experienced a durable complete response and remains cancer-free as of February 2020. In the second half of 2020, CNS expects to commence a Phase 2 clinical trial of Berubicin for the treatment of GBM in the U.S., while a sub-licensee partner undertakes a Phase 2 trial in adults and a first-ever Phase 1 trial in pediatric GBM patients in Poland. Its second drug candidate, WP1244, is a novel DNA binding agent that has shown in preclinical studies that it is 500-times more potent than the chemotherapeutic agent daunorubicin in inhibiting tumor cell proliferation. For more information, please visit www.cnspharma.com.
Company Details
- Employees
- 9
- Founded
- -
- Address
- Houston, Tx 77027, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- cnspharma.com
- Keywords
- Biotechnology, Pharmaceuticals, Healthcare.
- HQ
- Houston, TX
Cns Pharmaceuticals, Inc. Questions
Cns Pharmaceuticals, Inc.'s website is cnspharma.com
Cns Pharmaceuticals, Inc.'s LinkedIn profile is https://www.linkedin.com/company/cnspharma
Cns Pharmaceuticals, Inc. has
9 employees.
View email and phone details for 9
employees at Cns Pharmaceuticals, Inc..
Cns Pharmaceuticals, Inc.'s industry is
Biotechnology Research
Cns Pharmaceuticals, Inc.'s top competitors are
Alpha-9 Oncology,
Agomab,
Sorrento Therapeutics, Inc.,
Calidi Biotherapeutics,
Septerna,
March Biosciences,
Epitopea,
Axonis Therapeutics,
Pathos,
Annexon Biosciences.
Cns Pharmaceuticals, Inc.'s categories are Biotechnology Research
Cns Pharmaceuticals, Inc.'s founding year is 2017
